Stock TRAW TRAWS PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Traws Pharma, Inc.

Equities

TRAW

US68232V8019

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
0.6655 USD -0.82% Intraday chart for Traws Pharma, Inc. -4.40% -10.74%
Apr. 04 North American Morning Briefing : Focus Turns to -2- DJ
Apr. 04 Traws Pharma, Inc. Announces Chief Executive Office Changes CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
North American Morning Briefing : Focus Turns to -2-
DJ
Traws Pharma, Inc. Announces Chief Executive Office Changes
CI
Traws Pharma, Inc. Announces Board Changes
CI
Onconova Therapeutics Shares Drop; Company to Merge With Trawsfynydd Therapeutics
MT
Transcript : Onconova Therapeutics, Inc. - M&A Call
Traws Pharma Announces New Employee Inducement Grants
AQ
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company
AQ
Onconova Therapeutics, Inc and Trawsfynydd Therapeutics, Inc. Announce Management Appointments for the Combined Company Traws Pharma, Inc
CI
Onconova Therapeutics, Inc. completed the acquisition of Trawsfynydd Therapeutics, Inc.
CI
Onconova Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Traws Pharma, Inc. announced that it has received $14 million in funding from OrbiMed Advisors LLC, Torrey Pines
CI
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
AQ
Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma
AQ
Onconova TherapeuticsNarazaciclib Ash Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma
CI
Onconova Therapeutics Preclinical Narazaciclib Data At SABCS Highlights Differentiated Anti-Tumor Activity V. Other CDK4/6i's
AQ
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
AQ
Onconova Therapeutics? Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i?s
CI
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets Nineteenth Annual Emerging Growth Equity Conference
AQ
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
AQ
Transcript : Onconova Therapeutics, Inc., Q3 2023 Earnings Call, Nov 14, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TRAW Stock
  4. News Traws Pharma, Inc.